Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Intensity Therapeutics (NASDAQ:INTS) and maintained a $12 price target.
May 16, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Intensity Therapeutics and maintained a $12 price target.
The reiteration of a Speculative Buy rating and the maintenance of a $12 price target by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for Intensity Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100